Please Wait
Applying Filters...
menu
    • menu
    EUROAPI, the leading small molecules API player, provides both API sales & CDMO services.

    Virtual Booth

    Contact Supplier

    SPI Pharma has been solving formulation challenges using superior functional materials.

    Virtual Booth

    Contact Supplier

    Interquim comes from an international group of 50 companies active in the pharma, hospital, diagnostics, fine chemicals & feed sectors.

    Virtual Booth

    Contact Supplier

    Cohance Lifesciences, offers full range of CDMO services for small molecule APIs, intermediates, ADCs, Pellets and Formulations.

    Virtual Booth

    Contact Supplier

    FAMAR CDMO- From early development to commercial manufacturing.

    Virtual Booth

    Contact Supplier

    Polfa Tarchomin is a leading Polish pharmaceutical company with 200 year tradition in manufacture and sale of pharmaceutical products.

    Virtual Booth

    Contact Supplier

    Menu

    Regorafenib

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    REF. STANDARDS & IMPURITIES

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Takeda Receives EU Approval for FRUZAQLA
    Takeda Receives EU Approval for FRUZAQLA

    22 Jun 2024

    // PRESS RELEASE

    https://www.takeda.com/newsroom/newsreleases/2024/approval-from-european-commission-for-fruzaqla/

    PRESS RELEASE
    22 Jun 2024
    Share Share
    EpicentRx to Present for PII Trial to Assess Efficacy of RRx-001 vs. regorafenib
    EpicentRx to Present for PII Trial to Assess Efficacy of RRx-001 vs. regorafenib

    20 Jan 2023

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/epicentrx-announces-presentation-for-phase-2-randomized-active-controlled-multicenter-trial-to-assess-the-safety-and-efficacy-of-rrx-001-vs-regorafenib-in-thirdfourth-line-colorectal-cancer-at-the-2023-american-society-of-clin-301726884.html

    PR NEWSWIRE
    20 Jan 2023
    Share Share
    RRx-001 + Irinotecan Significantly Improved PFS Versus Regorafenib in PII Trial
    RRx-001 + Irinotecan Significantly Improved PFS Versus Regorafenib in PII Trial

    14 Dec 2022

    // PRNEWSWIRE

    https://www.prnewswire.com/news-releases/rrx-001--irinotecan-significantly-improved-progression-free-survival-pfs-versus-regorafenib-in-the-randomized-phase-2-rocket-trial-in-advanced-colorectal-cancer-301702337.html

    PRNEWSWIRE
    14 Dec 2022
    Share Share
    GCAR Announces That Regorafenib Has Completed Follow-up in the GBM AGILE Trial
    GCAR Announces That Regorafenib Has Completed Follow-up in the GBM AGILE Trial

    21 Sep 2022

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20220921005372/en

    BUSINESSWIRE
    21 Sep 2022
    Share Share
    Deciphera Receives EC Approval of QINLOCK for Gastrointestinal Stromal Tumor
    Deciphera Receives EC Approval of QINLOCK for Gastrointestinal Stromal Tumor

    22 Nov 2021

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20211122005306/en

    BUSINESSWIRE
    22 Nov 2021
    Share Share
    Pimitespib Prolongs Survival in Refractory Gastrointestinal Stromal Tumour
    Pimitespib Prolongs Survival in Refractory Gastrointestinal Stromal Tumour

    07 Jun 2021

    // FIRSTWORLDPHARMA

    https://www.firstwordpharma.com/node/1835415?tsid=4

    FIRSTWORLDPHARMA
    07 Jun 2021
    Share Share